Clinical observation on cetuximab(C225) with FOLFOX4 in the treatment of metastatic colorectal cancer

VernacularTitle:西妥昔单抗联合FOLFOX4方案治疗转移性结直肠癌临床观察
Author: Xiaohui XU ; Rui MA ; Linlin LI ; Bin LIU
Publication Type:Journal Article
Keywords: Colorectal neoplasms; Antineoplasms combined chemotherapy protocols; Cetuximab (C225); Oxaliplatin
From: Cancer Research and Clinic 2009;21(10):695-696
CountryChina
Language:Chinese
Abstract: Objective To evaluate the efficacy and safety of cetuximab(C225) with FOLFOX4 in the treatment of metastatic colorectal cancer (mCRC). Methods 68 patients with mCRC diagnosed by pathology were randomized in two groups: cetuximab combination with FOLFOX4 chemotherapy (combined group) and FOLFOX4 chemotherapy only (control group). Results The overall response rates (RR=CR+PR)in the combined group and the control group were 57.6 % and 32.3 % with significant difference (P <0.05). Grade Ⅲ/Ⅳ toxicity were myelosuppression(27.3 % and 32.4 %, P >0.05), nausea and vomiting(12.1% and 27.7 %, P >0.05), acne-like rash (only in combined group 9.1%). Conclusion The combination of cetuximab and chemotherapy can improve treatment efficacy. Except for rash, other grade Ⅲ/Ⅳ toxicity has no difference between the two groups.